Litcius/Paper detail

Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial

Eunice S. Wang, Ghayas C. Issa, Harry P. Erba, Jessica K. Altman, Pau Montesinos, Stephane DeBotton, Roland B. Walter, Kristen Pettit, Michael R. Savona, Mithun Vinod Shah, Marina Kremyanskaya, Maria R. Baer, James M. Foran, Gary J. Schiller, Lionel Adès, Maël Heiblig, Céline Berthon, Pierre Péterlin, Eduardo Rodríguez‐Arbolí, Olga Salamero, Mrinal M. Patnaik, Cristina Papayannidis, Jolanta Grembecka, Tomasz Cierpicki, Bradley Clegg, Joshua Ray, Brian M. Linhares, Kun Nie, Amitava Mitra, Julie Mackey Ahsan, Marilyn Tabachri, Harris S. Soifer, Daniel Corum, Mollie Leoni, Stephen Dale, Amir T. Fathi

2024The Lancet Oncology95 citationsDOI

Topics & Concepts

Open labelMyeloid leukaemiaMedicineRefractory (planetary science)CohortInternal medicineOncologyClinical trialBiologyAstrobiologyAcute Myeloid Leukemia ResearchChronic Myeloid Leukemia TreatmentsLung Cancer Treatments and Mutations
Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial | Litcius